Introduction {#Sec1}
============

Mass spectrometry using electrospray ionization (ESI-MS) in native conditions has been pioneered in 1991 by two almost simultaneous studies, one on the observation of enzyme--substrate and enzyme--product complexes \[[@CR1]\] and another one on the observation of the heme--globin complex in native hemoglobin \[[@CR2]\]. Since then, ESI-MS in native conditions has become common usage for studying noncovalent biological complexes \[[@CR3]\]. However, a major problem attached to this approach is the possible partial dissociation of the complex following the transfer into the gas phase. This is known as gas-phase dissociation (GPD), first studied quantitatively in \[[@CR4]\]. This is a major practical problem because in the absence of additional information, it is difficult to disentangle the amount of GPD from the determination of the dissociation constant *K* ~*d*~ characterizing the interaction. This difficulty stems from the fact that by ignoring the existence of GPD, an apparent *K* ~*d*~^*app*^ may often account reasonably for the experimental data from a titration experiment (see section '*To which extent can a single K* ~*d*~ *explain data affected by GPD?*' in Supplementary Data for a quantitative discussion of this problem). In any case, an increase of GPD leads to an apparent affinity lower than the real one (hence to *K* ~*d*~^*app*^ higher than *K* ~*d*~). This becomes crucial due to the so-called 'aggregation problem,' which is an opposite effect resulting from the strengthening of nonspecific electrostatic interactions in the gas phase. This was particularly clear with positively charged antibiotics interacting with RNA \[[@CR5]\]. It is then quite possible that these nonspecific and irrelevant interactions can be mistakenly considered as genuine specific interactions, particularly if the latter were thought to be lowered by GPD. In the field of drug development, this may become a serious problem, particularly when searching for a lead compound that is expected to bind poorly. Several lines of investigation have been undertaken, either to minimize the problem or to take it into account at the data-processing stage. Minimization of GPD has been obtained by using additives such as imidazole or sulfur hexafluoride in the gas phase \[[@CR6], [@CR7]\]. The favorable effect preserving the integrity of the complex of interest is thought to be due to evaporative cooling of the additive evacuating extra energy from the collisions with the neutral-gas molecules. Another possibility is the use of infrared radiation to heat the molecular complexes in the gas phase and dissociate nonspecific interactions \[[@CR8]\]. However, a sufficient difference in stability of the specific and nonspecific interactions is necessary to avoid dissociating significantly the specific interactions too. Another method, not for minimizing GPD but to quantify it, is to introduce both the protein of interest and an unrelated protein as a reporter for aggregation \[[@CR9]--[@CR11]\]. The latter method was thought to be misleading for aggregation resulting from strong electrostatic interactions and was thus modified by using a reference cognate ligand competing with a putative ligand for the same site \[[@CR12]\]. Finally, a processing method taking into account directly the amount of GPD (in conjunction with a micro gel filtration step to remove excess of ligand) was proposed \[[@CR13]\].

Here we show that with a dimeric protein with two equivalent and independent binding sites, the previously mentioned problems resulting from the correlation between the *K* ~*d*~ and the amount of GPD are considerably minimized for two reasons. First, instead of only one independent titration curve to be explained (fraction of complex versus concentration of the ligand), there are now two independent experimental curves to be explained (fractions of singly- and doubly occupied dimers versus concentration of the ligand), which represents an important increase of experimental information. Furthermore, there are no additional free parameters to be adjusted to account for this 2-fold amount of information. As a consequence, contrary to the previous situation, it is now mathematically impossible to obtain a single *K* ~*d*~^*app*^ accounting for the two independent experimental curves if one ignores the existence of GPD. In fact, it may be shown that there is a mathematical solution for *K* ~*d*~^*app*^ explaining the evolution of the fraction of singly occupied dimers, but it often leads to absurd negative values, and there is no solution at all explaining the evolution of the fraction of doubly occupied dimers. As a result, the important correlation between *K* ~*d*~ and GPD with a monomeric macromolecule disappears completely with a dimer having two identical and independent binding sites. We show in the following that not only the *K* ~*d*~ for the specific protein/ligand interaction and the amount of GPD but also (in one case) a *K* ~*d*~ **-**like value for nonspecific aggregation could be determined accurately. Importantly, this was achieved without recourse to additional experimental steps such as the use of (1) gas additives, (2) a reference protein (or ligand), and/or (3) a chromatographic step prior to injection in the instrument.

In the frame of an ongoing study on the search for new antibiotics, we focus in this work on the interaction of three synthetic peptide ligands (Supplementary Figure [S2](#MOESM1){ref-type="media"}) with three DNA-polymerase processivity factors (β-rings) from bacterial origin (*Escherichia coli*, *Mycobacterium tuberculosis*, and *Pseudomonas aeruginosa*) \[[@CR14], [@CR15]\]. These β-rings are homodimers (Figure [1](#Fig1){ref-type="fig"}) that bind specifically the ligands \[[@CR16], [@CR17]\]. The synthetic peptides were derived from the natural peptides that are present in each DNA-polymerase and that mediate the DNA-polymerase/β-ring interaction \[[@CR18]\].Figure 1Illustration of the ring species *R* ~*0*~, *R* ~*1*~ and *R* ~*2*~ *.* Structure of the *E.coli* processivity factor \[[@CR13]\]. Each specifically-bound peptide is represented as a sphere at the position known from X-ray crystallography \[[@CR16]--[@CR18]\]. Nonspecific binding site(s) for a third peptide discussed in the following is (are) not known

Experimental {#Sec2}
============

Protein Production and Purification {#Sec3}
-----------------------------------

The three *dnaN* bacterial genes were cloned into pET15b plasmid (Invitrogen, Carlsbad, CA, USA) using standard protocols. The resulting N-tagged protein was expressed in BL21 *E. coli* cells after IPTG induction (0.1 mM) at 28 °C. The β protein fractions were first enriched on a Ni-NTA column, eluted with a histidine step (300 mM), and further purified on a MonoQ column in buffer containing 20 mM Tris HCl pH 7.5, 0.5 mM EDTA, and 10% glycerol, using a gradient from 0 to 0.5 M NaCl. The purified proteins were dialyzed and concentrated (around 300 μM) against buffer containing 20 mM Tris HCl pH 7.5, 0.5 mM EDTA, and 10% glycerol.

Peptide Synthesis {#Sec4}
-----------------

Procedures for the synthesis of the different peptides used in this study (**P6**, **P11**, and **P14**) have been described elsewhere \[[@CR17]\]. The chemical-structure formulae of the peptides are shown in Supplementary Figure [S2](#MOESM1){ref-type="media"}.

Mass Spectrometry Measurements {#Sec5}
------------------------------

Mass spectrometry studies were performed on a Micromass Q-Tof Micro (Waters Milford, MA, USA). ESI conditions were optimized to preserve the noncovalent complexes during the ionization-desorption process. To reach sufficient desolvation while minimizing dissociation of the noncovalent dimers, accelerating cone voltage was tuned to 100 V, extraction cone to 30 V, and desolvation temperature to 150 °C \[[@CR19]\]. The pressure in the interface region was increased by 2.4 to 4.5 mbar to increase the signal-to-noise ratio \[[@CR20]\]. Data were acquired in positive ion mode and accumulated during 3 min for each sample.

ESI-MS Titration Experiments {#Sec6}
----------------------------

Peptide stock solutions were prepared by dissolving peptides to 3.8 mM in 100% DMSO. For all titration experiments, the different proteins were at a constant monomer concentration of 0.6 μM in 50 mM ammonium acetate, pH 7. Peptides were added at 22.5 °C just before injection to avoid aggregation. The final DMSO concentration was maintained to 1% (v/v) to keep the same protein charge state for each titration point. Table [1](#Tab1){ref-type="table"} gives the concentrations used in the titration experiments.Table 1Protein and Peptide Characteristics*E. coli*43286**P6**676.80.12, 0.28, 0.49, 0.75, 1.1, 1.5, 2.1, 2.9, 3.8, 5.1, 6.0**P11**730.40.08, 0.18, 0.31, 0.47, 0.67, 0.93, 1.3, 1.7, 2.2, 2.8, 3.6, 4.7**P14**785.70.03, 0.06, 0.1, 0.15, 0.2, 0.28, 0.36, 0.46, 0.59, 0.74, 0.92, 1.4, 2.0*M. tuberculosis*44276**P14**785.70.12, 0.28, 0.49, 0.75, 1.1, 1.5, 2.1, 2.9, 3.8, 5.1, 6.0*P. aeruginosa*42727**P11**730.40.08, 0.18, 0.31, 0.47, 0.67, 0.93, 1.3, 1.7, 2.2, 2.8, 3.6, 4.7**P14**785.70.03, 0.06, 0.1, 0.15, 0.2, 0.28, 0.36, 0.46, 0.59, 0.74, 0.92, 1.4, 2.0The molecular weights (g mol^−1^) of the protein monomers (col. 2) and of the peptides **P6**, **P11**, and **P14** (col. 4) are indicated. Last column: peptide concentrations (μM) used for each titration

ESI-MS Data Processing {#Sec7}
----------------------

Raw spectra were obtained as Excel files and processed entirely with our own programs developed with *Mathematica* from Wolfram Research. The data were first smoothed with a moving Gaussian filter on 30 successive points. Since the protein monomers are tightly associated as dimeric rings, there are two specific peptide binding sites on each ring (Figure [1](#Fig1){ref-type="fig"}). As a consequence, we always observed at least three types of complexes *R* ~*i*~ (*i* = 0, 2), corresponding to rings with no bound peptide (*i* = 0), one bound peptide (*i* = 1) and two bound peptides (*i* = 2) (Figure [2](#Fig2){ref-type="fig"}). In some cases, we also observed nonspecific weak binding (or 'aggregation') of a third peptide giving rise to the species *R* ~3~. This was particularly clear for β~*E.coli*~/**P6** (Figure [2](#Fig2){ref-type="fig"}). Quantification of the three- or four-species spectra was performed by considering the free-ring spectra at various charge states *z* as rulers for the recovery of the fractions of the species *R* ~0~, *R* ~1~, *R* ~2~ (and possibly *R* ~3~) with the same charge state (Figure [3](#Fig3){ref-type="fig"}). This was achieved with a classic linear least-squares method by considering, for each charge state *z,* that:$$\documentclass[12pt]{minimal}
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For the determination of *K* ~*d*~ values, the resulting small fraction *r* ~3~, if any, was simply added to the fraction *r* ~2~ since *R* ~3~ can only be formed from *R* ~2~. With the pair β~*E.coli*~/**P6**, for which *R* ~3~ appeared clearly, a specific treatment not merging *r* ~3~ with *r* ~2~ (see below) allowed us to derive a *K* ~*d*~ -like value for the weak binding. Exceptionally, the species *R* ~4~ was also detected but its level was very low and it was ignored.

Determination of the K~d~ Values from MS-ESI Experiments {#Sec8}
--------------------------------------------------------

The two binding sites on each ring are maximally distant from one another since they are located at both ends of a ring diameter (Figure [1](#Fig1){ref-type="fig"}) and, therefore, may safely be considered as independent binding sites. As a consequence, in solution, the set of theoretical *r* ~*n*~ values only depends on the dissociation constant *K* ~*d*~ of the monomer/peptide equilibrium. The equilibrium concentrations *M* ~0~ of free monomers, and *M* ~1~ of monomers bound to one peptide, are:$$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ {M}_0=\frac{1}{2}\left({M}_{tot}-{P}_{tot}-{K}_d+\sqrt{{\left({K}_d+{M}_{tot}+{P}_{tot}\right)}^2-4{M}_{tot}{P}_{tot}}\right) $$\end{document}$$ $$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ {M}_1=\frac{1}{2}\left({M}_{tot}+{P}_{tot}+{K}_d-\sqrt{{\left({K}_d+{M}_{tot}+{P}_{tot}\right)}^2-4{M}_{tot}{P}_{tot}}\right) $$\end{document}$$where *P* ~*tot*~ and *M* ~*tot*~ are, respectively, the total concentrations of peptide and of protein monomer (twice the β-ring concentration). The corresponding molar fractions are *m* ~0~ = *M* ~0~ /*M* ~*tot*~ and *m* ~1~ = *M* ~1~ /*M* ~*tot*~. The molar fractions *r* ~0~, *r* ~1~, *r* ~2~ of the ring species *R* ~0~, *R* ~1~, *R* ~2~ can then be derived from a thought-experiment consisting in assembling ring dimers by randomly picking monomers among *M* ~0~ and *M* ~1~ species, which leads to the classical binomial distribution:$$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \begin{array}{ccc}\hfill {r}_0={m}_0^2,\hfill & \hfill {r}_1=2{m}_0{m}_1,\hfill & \hfill {r}_2={m}_1^2\hfill \end{array} $$\end{document}$$

To take into consideration peptide loss due to gas-phase dissociation (GPD), Equations [3a](#Equ4){ref-type=""} have to be modified by introducing the probability *P* of dissociation of $\documentclass[12pt]{minimal}
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Equation [3a](#Equ4){ref-type=""} corresponds to the fractions in solution, whereas Equation [3b](#Equ5){ref-type=""} corresponds to the fractions actually measured in the spectrometer. Note that *P* is equivalent to the term 1 − *f* ~*sat*~ in a study that also focused on taking into account the influence of GPD \[[@CR13]\]. Therefore, the fitting of the set of experimental values *r* ~0~, *r* ~1~, *r* ~2~ for various peptide concentrations requires determining *K* ~*d*~ and *P*, which was performed by a nonlinear regression procedure. We also introduced the possibility of a third free parameter *α* corresponding to a multiplicative factor for the total peptide concentration. This was done in view of detecting possible errors in the peptide or protein concentrations (or effective concentrations). Indeed, if α is adjusted to a value lower/higher than 1, this means that either the peptide concentration was over/underestimated in comparison with that of the protein or, equally well, that the protein concentration was under/overestimated in comparison with that of the peptide (which alternative is the correct one cannot be decided). Such a method is the rule when using ITC. Each time, it was examined whether using three free parameters (*K* ~*d*~, *P* and α) yielded significantly better result than *K* ~*d*~, *P* alone with α fixed to 1. When the gain was marginal we reported the results with *K* ~*d*~, *P* alone.

Although the weak nonspecific binding most likely arises from aggregation in the gas phase and is not representative of true equilibrium in solution, we examined whether a *K* ~*d*~ -like value would account for this weak binding, particularly with β~*E.coli*~/**P6** for which it is clearly visible. For that, the fraction *r* ~3~ of beta-ring with three bound peptides was not merged with *r* ~2~ and Equations [3b](#Equ5){ref-type=""} had to be generalized as follows:$$\documentclass[12pt]{minimal}
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                \begin{document}$$ {r}_0={\left[{m}_0+P\;\left({m}_1+{m}_2\right)\right]}^2,{r}_1=2\left[{m}_0+P\;\left({m}_1+{m}_2\right)\right]\left[\left(1-P\right)\left({m}_1+{m}_2\right)+P\;{m}_{1,2}\right],{r}_2={\left(1-P\right)}^2{\left({m}_1+{m}_2\right)}^2+{P}^2{m}_{1,2}^2+2\left[\left({m}_0+P\;{m}_1+P\;{m}_2\right)\left(1-P\right){m}_{1,2}+{P}^2{m}_{1,2}^2\right]{r}_3=2\left(1-P\right){m}_{1,2}\left[\left(1-P\right)\left({m}_1+{m}_2\right)+P\;{m}_{1,2}\right], $$\end{document}$$with *m* ~2~ standing for the molar fraction of monomers with only one weakly bound peptide and *m* ~1,2~ for the molar fraction of doubly occupied monomers (both in the strong specific and weak nonspecific binding sites). Making *m* ~2~ = *m* ~1,2~ = 0 in Equations [4](#Equ6){ref-type=""} yields Equations [3b](#Equ5){ref-type=""} and *r* ~3~ = 0, as expected. The very small fraction *r* ~4~ of beta-rings with four bound peptides was ignored. The variations of the molar fractions *r* ~0~, *r* ~1~, *r* ~2~ , *r* ~3~ with the concentration *P* ~*tot*~ were then fit with a simple model of two independent sites with dissociation constants *K* ~*d*1~ ≈ *K* ~*d*~ and *K* ~*d*2~ \> \> *K* ~*d*~. This obviously does not mean that the weak interaction is mediated by a single site, as the unique *K* ~*d*2~ may well lump together the influence of several weak aggregation sites (possibly following a Poisson distribution as explained in \[[@CR21]\]). Note also that using a single value *P* to represent the GPD for both sites, instead of *P* ~1~ with *K* ~*d*1~ and *P* ~2~ with *K* ~*d*2~, is a simplification justified *a priori* by the need of minimizing the number of free parameters and *a posteriori* by the fact that no correlation between *K* ~*d*~ and *P* was observed (Supplementary Figure [S7](#MOESM1){ref-type="media"}).

ITC Measurements and ITC-Data Processing {#Sec9}
----------------------------------------

We used an iTC200 from Microcal (now Microcal-Malvern, UK) operated in the high-gain mode. The experimental procedure was described in \[[@CR16]\]. In short, the *β* -rings were initially in the cell at concentrations ranging from 20 to 60 μM and the peptides were in the syringe at concentrations ranging from 200 to 600 μM. The buffer was Hepes 10 mM, pH 7.4, supplemented with NaCl 150 mM and EDTA 3 mM. Experiments were performed at different temperatures from 15 to 34 °C.

The processing of the ITC data was first performed with the same model as the one used for ESI-MS (one specific binding site per monomer). Since the titration experiments with the same protein-peptide pair were performed at different temperatures, we used a procedure that we have termed 'Global Thermodynamic Treatment' (GTT), wherein all titration experiments at different temperatures have to be fit at once, and not separately \[[@CR22]\]. The advantage of this still unusual method is of fitting several titration curves with a minimum set of free parameters. All *K* ~*d*~ values obtained by ITC were corrected for 22.5 °C, which was the incubation temperature used in ESI-MS experiments. This was performed by using the Van't Hoff equation: ∂ ln *K* ~*d*~/∂*T* = − *ΔH*/(*RT* ^2^), where *ΔH* is the variation of enthalpy during complex formation and ***R*** = 8.314 J mol^−1^ K^−1^ the gas constant. Note that such a correction is quite justified for *K* ~*d*~ values obtained by ITC since the primary output from ITC is precisely the enthalpic term *ΔH* governing the evolution of *K* ~*d*~ with the temperature. In addition, the extrapolation of *K* ~*d*~ at 22.5 °C was always performed from a temperature close to 22.5 °C.

The latter simple processing method did not allow us to obtain a correct fit of several ITC data and, therefore, we attempted to use a more complex (but classic) model by considering a competition between two modes of binding on the same site. Note that the results from ESI-MS imposed to use a competition model for the same site, and not the binding to another site, since ESI-MS did not show the binding of a second peptide per monomer with sufficient affinity to explain the observed lacks of fit. This competition model requires determining a fixed fraction *f* ~1~ of the protein monomers binding their ligand according to a dissociation constant *K* ~*d*1~ and an enthalpy variation *ΔH* ~1~, and a fixed fraction *f* ~2~ = 1 − *f* ~1~ binding their ligand according to a dissociation constant *K* ~*d*2~ and an enthalpy variation *ΔH* ~2~ (we consider *K* ~*d*2~ \< *K* ~*d*1~).

Finally, since it appeared clearly with the ESI-MS data from β~*E.coli*~/**P6** (Figure [2](#Fig2){ref-type="fig"}) that a third peptide (and marginally a fourth peptide) could bind the *β* -ring, it was attempted to see whether this weak association was detectable in the ITC data from β~*E.coli*~/**P6**. At variance with the previous situation, it was thus necessary to use a binding model with (at least) two independent binding sites on each monomer to account for the simultaneous binding of three peptide molecules per dimer.

All data processing was performed with our own methods programmed with *Mathematica* (Wolfram Research).

Results and Discussion {#Sec10}
======================

Determination of the Fractions *r*~*n*~ by Fitting of the Experimental Spectra {#Sec11}
------------------------------------------------------------------------------

The raw experimental spectra are in Figure [2](#Fig2){ref-type="fig"} and Supplementary Figure [S3](#MOESM1){ref-type="media"}. Although the individual peaks are broad, they show well the successive apparition of *R* ~1~, *R* ~2~ (and possibly *R* ~3~) species upon peptide concentration increase. Figure [4](#Fig4){ref-type="fig"} (β~*Ecoli*~ /**P6**) and Supplementary Figure [S4A](#MOESM1){ref-type="media"} (β~*Pseudomonas*~/**P14**) show two examples of fits obtained for the complete experimental spectra by using the free-ring spectrum as a ruler. For these two cases, the results were very good (particularly for β~*Pseudomonas*~/**P14** in Supplementary Figure [S4A](#MOESM1){ref-type="media"}) due to the shape of each free-ring spectrum being quite representative of the shape of each peak in the composite spectra. However, this was not always the case and, in situations where there was a significant broadening of all peaks (obtained in presence of peptide) in comparison of the peak *R* ~0~ serving as a ruler (obtained without peptide), the quality was affected, as expected. We can only invoke for this dependence of spectral quality on the nature of the beta ring and on the nature of the peptide a variable influence of desalting and of DMSO. The worst result was for β~*Pseudomonas*~/**P11** shown in Supplementary Figure [S4B](#MOESM1){ref-type="media"}. One may consider for the future an improvement of the fitting method by constructing, when necessary, a composite ruler. Indeed, Supplementary Figure [S4B](#MOESM1){ref-type="media"} shows that overall the peaks retain the same composite shape during a titration. In fact, this method could be put into practice simply by using as a ruler the peak *R* ~0~ obtained at the lowest ligand concentration, not at null concentration.Figure 4Fit of the experimental spectra for β~*E.coli*~ */*P6. The experimental spectra for z = +18 (blue curves) are those in Figure [2](#Fig2){ref-type="fig"} for β~*E.coli*~/**P6** and, for three of them (0, 0.28, and 2.9 μM), correspond to the spectra in Figure [3](#Fig3){ref-type="fig"} (with z = +17, hence the differences in *m/z*). The theoretical spectra (red curves) obtained from Equation [1](#Equ1){ref-type=""} are also shown. The peak for *R* ~3~ at *m/z* ≈ 4925 starts emerging at \[P6\] = 0.75 μM and then appears clearly. A very faint fourth peak corresponding to the species *R* ~4~ begins to appear at the highest concentrations of **P6** but was ignored

From these fits, we obtained the sets of the fractions *r* ~*n*~ of all *R* ~*n*~ species for each ligand concentration. A subset of the results is shown in Figure [5](#Fig5){ref-type="fig"} and all results in Supplementary Figure [S5B](#MOESM1){ref-type="media"}. In all situations, the evolutions of the concentrations of the three species *R* ~0~, *R* ~1~, *R* ~2~ are well-defined with a maximum for the intermediate species *R* ~1~. It is also to be noted that there is a clear lag in the appearance of *R* ~2~ (see, in particular, β~*Mycobacterium*~/**P14** in Figure [5](#Fig5){ref-type="fig"}), which is in line with the expectation since *R* ~2~ can appear only after *R* ~1~ has sufficiently accumulated.Figure 5Experimental fractions of the species *R* ~0~, *R* ~1~, *R* ~2~ and theoretical curves. Experimental fractions for the species *R* ~0~, *R* ~1~, *R* ~2~ and theoretical fits (solid curves) with the indicated values for *K* ~*d*~ and *P* for a subset of all titration curves. All other curves are in Supplementary Figure [S5B](#MOESM1){ref-type="media"}. The analysis of the errors and the correlation between parameters are shown in Supplementary Figure [S6](#MOESM1){ref-type="media"}. The inclusion of *R* ~3~ in the processing is described later in the text for β~*Ecoli*~ /**P6** and the result is shown in Supplementary Figure [S5C](#MOESM1){ref-type="media"}

Determination of *K*~*d*~ and GPD Probability *P* Values {#Sec12}
--------------------------------------------------------

These experimentally-derived titration curves in Figure [5](#Fig5){ref-type="fig"} were fit by using Equations [2a](#Equ2){ref-type=""}, [2b](#Equ3){ref-type=""} and Equation [3b](#Equ5){ref-type=""} to obtain the values of *K* ~*d*~, *P* (and possibly α). Figure [5](#Fig5){ref-type="fig"} also shows the best fit obtained after minimization of the residual sum of squares (SOS). An analysis of the parameter errors and correlations shows systematically the same pattern (Supplementary Figure [S6](#MOESM1){ref-type="media"}). In all situations, the SOS has a well-defined minimum and the pairs *K* ~*d*~ and *P*, or *K* ~*d*~ and α are anti-correlated in such a way that increasing/decreasing *K* ~*d*~ slightly from its best value minimizing the SOS is compensated for by decreasing/increasing slightly *P* or α from their best values.

The probabilities *P* of GPD that we obtained never exceed 12%, which is in line with the low cone voltage fixed to 100 V. Such a maximum value of 12% is low in comparison with the values reported in \[[@CR13]\] that ranged from 0 to 75%. However, in \[[@CR10]\]*,* the cone voltage was tuned differently for each ligand and it is likely that values higher than 100 V were used. We note that the distribution of these probability values does not show any correlation with the affinity of the peptide ligand for its protein target but, instead, shows a clear correlation with the nature of the peptide (Supplementary Figure [S7](#MOESM1){ref-type="media"}). This is in agreement with the conclusion from another study on protein--peptide interactions \[[@CR23]\]. Gathering the results from \[[@CR13]\] (which, apart one case among six, did not bear on protein--peptide interaction) also revealed a complete lack of correlation between $\documentclass[12pt]{minimal}
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                \begin{document}$$ {K}_d\left(\mathrm{E}\mathrm{S}\mathrm{I}\hbox{--} \mathrm{M}\mathrm{S}\right) $$\end{document}$ and *P* (not shown). This should not come as a surprise since a *K* ~*d*~ value results from the influence of both the association and dissociation steps, whereas the association step cannot have any influence in the gas phase essentially devoid of ligand. Therefore, only the dissociation step influences the value of *P* and, indeed, GPD is correlated with the activation energy for dissociation \[[@CR4]\].

Misleading Results from ITC {#Sec13}
---------------------------

The ITC titration curves and their fits with the same model as for ESI-MS data processing are shown in Supplementary Figure [S8](#MOESM1){ref-type="media"}. The comparison of the $\documentclass[12pt]{minimal}
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                \begin{document}$$ {K}_d\left(\mathrm{E}\mathrm{S}\mathrm{I}\hbox{--} \mathrm{M}\mathrm{S}\right) $$\end{document}$ and available *K* ~*d*~(ITC) values is shown in Figure [6](#Fig6){ref-type="fig"} (left panel). It appears that apart for an obvious outlier (β~*E.coli*~/**P6**), the two sets of results show good correlation. However, the $\documentclass[12pt]{minimal}
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                \begin{document}$$ {K}_d\left(\mathrm{E}\mathrm{S}\mathrm{I}\hbox{--} \mathrm{M}\mathrm{S}\right) $$\end{document}$ values were systematically lower than those from ITC. Letting aside β~*E.coli*~/**P6**, this inequality may be represented by $\documentclass[12pt]{minimal}
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                \begin{document}$$ {K}_d\left(\mathrm{I}\mathrm{T}\mathrm{C}\right)\approx {K}_d\left(\mathrm{E}\mathrm{S}\mathrm{I}\hbox{--} \mathrm{M}\mathrm{S}\right)+0.25\;\mu \mathrm{M} $$\end{document}$. This is only intended to represent in as simple a way as possible the relationship between the two sets of results.Figure 6Comparison of Kd(MS-ESI) and Kd(ITC) results. **Left panel:** processing of ITC data with one mode of binding. Each point is the average of all separate experiments for a given protein-peptide pair. The dashed line represents K~d~(ITC) = K~d~(MS-ESI). In one thus obtained K~d~(MS-ESI) \< K~d~(ITC) in all situations and, apart for the clear outlier β~*E.coli*~/**P6**, it appears that K~d~(ITC) -- K~d~(MS-ESI) ≈ 0.25 μM. The shaded strip of width 0.3 μM represents the 95% confidence interval for K~d~(ITC) -- K~d~(MS-ESI), which means that excluding β~*E.coli*~/**P6**, one has the inequality 0.15 μM \< K~d~(ITC) -- K~d~(MS-ESI) \< 0.35 μM with a probability of 95%. The data highlighted with a red dot are re-examined in the right panel. **Right panel:** processing of ITC data with two modes of binding on the same site. The ITC data for β~*E.coli*~/**P6**, β~*E.coli*~/**P14** and β~*Pseudomonas*~/**P14** (red dots in the left panel) could be processed with a model involving two modes of binding on the same specific site (see text). This led to a high- and a low-affinity binding. The dark-blue symbols correspond to the previous results in the left panel and the red symbols correspond to the new ITC results for the high-affinity mode of binding (the ITC results for the low-affinity mode of binding are close to the results in the left panel and are shown in Supplementary Figures [S9](#MOESM1){ref-type="media"} and [S10](#MOESM1){ref-type="media"}). In all three cases these high-affinity K~d~(ITC) values are close to the dashed line representing K~d~(ITC) = K~d~(MS-ESI)

It is often mentioned that an increase of the ligand concentration during the desolvation step might induce an apparent increase in the affinity, and thus a $\documentclass[12pt]{minimal}
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                \begin{document}$$ {K}_d\left(\mathrm{E}\mathrm{S}\mathrm{I}\hbox{--} \mathrm{M}\mathrm{S}\right) $$\end{document}$ lower than *K* ~*d*~(ITC) in solution, as we observed. However, we note that this tendency $\documentclass[12pt]{minimal}
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                \begin{document}$$ {K}_d\left(\mathrm{I}\mathrm{T}\mathrm{C}\right)>{K}_d\left(\mathrm{E}\mathrm{S}\mathrm{I}\hbox{--} \mathrm{M}\mathrm{S}\right) $$\end{document}$ was not apparent in the results from \[[@CR13]\]. Furthermore, as explained in the 'Experimental section,' the model in use was too simple and a more sophisticated processing of the ITC data with two competing binding modes on the same site revealed another *K* ~*d*~(ITC) very close to $\documentclass[12pt]{minimal}
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                \begin{document}$$ {K}_d\left(\mathrm{E}\mathrm{S}\mathrm{I}\hbox{--} \mathrm{M}\mathrm{S}\right) $$\end{document}$ for three peptides (Figure [6](#Fig6){ref-type="fig"}, right panel). All fits for the reprocessed ITC curves are in Supplementary Figure [S9](#MOESM1){ref-type="media"} and all resulting parameter values are in Supplementary Figure [S10](#MOESM1){ref-type="media"}.

A striking conclusion arises from inspection of the results. Recall first that processing the ITC curves with the simplest usual model implies introducing a single pair of thermodynamic parameters (*K* ~*d*~, *ΔH*). On one hand, several fits were of insufficient quality (particularly β~*E.coli*~/**P14** at 20 °C, Supplementary Figure [S8](#MOESM1){ref-type="media"}). On the other hand, in several occasions the fits would have been accepted as such in most routine ITC studies (e.g., β~*E.coli*~/**P6** at 26 and 30 °C, β~*E.coli*~/**P14** at 30 °C in Supplementary Figure [S8](#MOESM1){ref-type="media"}). Since we know that lower *K* ~*d*~ values than those obtained by ITC (with the simplest model) are necessary to explain the ESI-MS titration curves, it is important to examine what kind of error is made if one remains content with the ITC results obtained with the simplest model. From Supplementary Figure [S10](#MOESM1){ref-type="media"} it appears that the model with two binding modes led to the 'blue' pair (*K* ~*d*1~, *ΔH* ~1~) and 'red' pair (*K* ~*d*2~, *ΔH* ~2~). For example, with β~*E.coli*~/**P6**, one obtained (*K* ~*d*1~ ≈ 1 μM, *ΔH* ~1~ ≈ 1 kcal mol^−1^) and (*K* ~*d*2~ ≈ 0.25 μM, *ΔH* ~2~ ≈ --12 kcal mol^−1^). Importantly, the simple method involving one binding mode led (at 25 °C) to the unique pair (*K* ~*d*~ = 1.4 ± 0.2 μM, *ΔH* ≈ --11.8 ± 0.2 kcal mol^−1^), which is striking as this corresponds to mixing of the two previous pairs by reporting the *K* ~*d*~ value of the weaker binding mode, but the *ΔH* value of the stronger binding mode. The reason for which this was possible stems from the very low \|*ΔH*\| value of the weaker binding mode, which almost erased its contribution in the overall amplitude of the titration curves, whereas the higher *K* ~*d*~ value (lower affinity) attached to this low \|*ΔH*\| value did influence the overall sigmoid shape of the titration curve by making it not too sharp. As a consequence, the too simple model 'did its best' to explain both the significant amplitude of the titration curves and the not-too-sharp return to base line by mixing wrongly the parameters from the two binding modes. Examination of Supplementary Figure [S10](#MOESM1){ref-type="media"} shows that the same problem arose in all other situations. To our knowledge, this is the first time that this kind of serious error is identified and established clearly thanks to ESI-MS.

Determination of a *K*~*d*~ for Describing Weak Nonspecific Binding (Aggregation) {#Sec14}
---------------------------------------------------------------------------------

Supplementary Figure [S5C](#MOESM1){ref-type="media"} (left panel) shows how the processing of the raw MS-ESI data from β~*E.coli*~/**P6** (Figure [2](#Fig2){ref-type="fig"}) led to the determination of the fraction *r* ~3~ besides those for *r* ~0~, *r* ~1~, *r* ~2~. Fitting these data with Equations [4](#Equ6){ref-type=""} led to convincing results with a value *K* ~*d*1~ = (0.166 ± 0.04) µM for the specific site very close to *K* ~*d*~ = (0.16 ± 0.04) µM obtained by merging the fraction *r* ~3~ with *r* ~2~ (Supplementary Figure [S5C](#MOESM1){ref-type="media"}, right panel), whereas *K* ~*d*2~ for the nonspecific weak site converged to the much higher value *K* ~*d*2~ = (42.6 ± 3) µM. The errors on *K* ~*d*1~ and *K* ~*d*2~ were estimated roughly by comparison with the results obtained from a duplicate experiment. It thus appears that both the specific and nonspecific bindings were very well characterized.

Importantly, all attempts at processing the ITC data from β~*E.coli*~/**P6** with the same binding model as the one used for MS-ESI, first, did not improve significantly the fit of the experimental titration curves shown in Supplementary Figure [S8](#MOESM1){ref-type="media"} and, second, led to extremely unstable results upon minor changes in baseline determination. For example, the value for *K* ~*d*2~ could jump from a reasonable value in the range of 20--30 μM (as observed with MS-ESI) to a value in the range 10--30 mM. One has thus to admit that no convincing results could be obtained by ITC with a binding model requiring two (or more) binding sites per monomer, which supports well that the nonspecific weak binding resulting from 'aggregation' due to the particular conditions in the ESI-MS experiments.

Although the peak for the species *R* ~3~ for β~*Mycobacterium*~/**P14** is visible on the raw spectra (Figure [2](#Fig2){ref-type="fig"}), the quality of the data was not sufficient for repeating successfully the same kind of analysis. For the complexes β~*E.coli*~/**P11** and β~*Pseudomonas*~/**P11**, the signal for the species *R* ~3~ was too faint (Supplementary Figure [S3](#MOESM1){ref-type="media"}) to attempt any processing. For the complexes β~*E.coli*~/**P14** and β~*Pseudomonas*~/**P14**, no signal for the species *R* ~3~ was detected. However, **P14** has the highest affinity for *E. coli* and *Pseudomonas* β-rings and, for this reason, the ESI-MS titrations did not use a concentration above 2 μM for **P14**, whereas the peptide concentration reached 4.7 and 6 μM for the other peptides (Table [1](#Tab1){ref-type="table"}). This most likely explains why weak nonspecific binding was not observed with β~*E.coli*~/**P14** and β~*Pseudomonas*~/**P14**.

Experimental Factors Limiting the Accuracy of MS-ESI Processing {#Sec15}
---------------------------------------------------------------

At the basis of the method in use is the fit of the experimental spectra (Figure [4](#Fig4){ref-type="fig"}) with the method described in Figure [3](#Fig3){ref-type="fig"} to obtain, at each ligand concentration, the set of the fractions *r* ~*n*~ for each *R* ~*n*~ species. It was rather surprising that obtaining an excellent fit of the experimental spectra was not sufficient to obtain a titration curve of excellent quality with the experimental points being smoothly distributed as with β~*Mycobacterium*~/**P14** in Figure [5](#Fig5){ref-type="fig"}. Only a set of such smooth curves may lead to a very low residual sum of squares (SOS), whereas a more erratic distribution of the experimental points (as with β~*E.coli*~/**P14** in Figure [5](#Fig5){ref-type="fig"}), being the mark of significant experimental noise, cannot lead to a very low SOS. Upon examination of the distribution of all SOS values, it appeared that these are anti-correlated with the maximum value of the peptide concentration used in the experiment (Supplementary Figure [S11](#MOESM1){ref-type="media"}). The interpretation of this observation is clear: when the affinity of the protein--peptide interaction was high, the maximum peptide concentration in use for the titration did not exceed 2 μM, which led to smaller dispensed volumes of the peptide stock solutions in comparison with situations where the maximum peptide concentration reached 6 μM. As a consequence, a lower relative accuracy of the final peptide concentration was obtained for the titrations performed with a maximum peptide concentration of 2 μM, which explains well the observed tendency in Supplementary Figure [S11](#MOESM1){ref-type="media"}. Examination of Figure [6](#Fig6){ref-type="fig"} (left panel), however, shows that this lower relative accuracy cannot account for the observed inequality $\documentclass[12pt]{minimal}
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Conclusion {#Sec16}
==========

We have obtained the *K* ~*d*~ values for the binding of peptides onto DNA-processivity β-rings from three bacterial organisms. Our ESI-MS data show very well the successive specific binding of two peptides per ring and, in several occasions, the nonspecific binding of a third peptide. We obtained accurate titration curves that often could only be processed to obtain the $\documentclass[12pt]{minimal}
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                \begin{document}$$ {K}_d\left(\mathrm{E}\mathrm{S}\mathrm{I}\hbox{--} \mathrm{M}\mathrm{S}\right) $$\end{document}$ values by taking into account the possibility of peptide loss due to GPD. In comparison, the fit of the ITC curves with the same model of binding was often poor and led to *K* ~*d*~(ITC) values linked to their ESI-MS counterparts by $\documentclass[12pt]{minimal}
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                \begin{document}$$ {K}_d\left(\mathrm{E}\mathrm{S}\mathrm{I}\hbox{--} \mathrm{M}\mathrm{S}\right) $$\end{document}$. Our results highlight the complementarity of the two techniques in use but also how ESI-MS can help obtain the correct results with ITC in ambiguous situations. On one hand, ESI-MS did not detect the weaker binding mode with the experimental procedure in use. In fact, it would be necessary to repeat these ESI-MS experiments by considering higher concentrations of the peptides and of the proteins to check whether this weaker binding mode is really present in the MS conditions. One could increase the protein concentration 10-fold (i.e., up to 6 μM), but certainly not up to the concentration range used in the ITC experiments (30--60 μM), which would lead to saturation of the instrument response and loss of linearity between concentration and peak amplitude. On the other hand, it happened that ITC detected with difficulty the major and stronger binding mode. In usual situations involving routine application of ITC, one may even consider that such ITC data would lead to serious errors by reporting the *K* ~*d*~ of the weaker and minor binding mode and the *ΔH* of the stronger and major binding mode. It is likely that such errors are to be found in published data.

One potential problem that may have plagued ITC measurements (and would explain why the weaker binding mode was absent in ESI-MS conditions), comes from the limited solubility of the peptides used. It is to be recalled that the peptides were in the syringe at a concentration ten times higher than the initial concentration of the protein in the cell. These peptide concentrations ranged from 200 to 400 μM for β~*E.coli*~/**P14** and β~*Pseudomonas*~/**P14**, but reached 500 μM for β~*Mycobacterium*~/**P14** and even 600 μM for β~*E.coli*~/**P6**. These are high concentrations and, although no problem was apparent during the ITC experiments, it is likely that the activity of the peptides was significantly less than for an ideal solution at these concentrations and, as a consequence, the affinity of these peptides for their target was apparently lower. In particular, it may be noted that β~*E.coli*~/**P6**, for which the discrepancy between MS-ESI and ITC was the highest (Figure [6](#Fig6){ref-type="fig"}), corresponds precisely to the highest peptide concentration used in the ITC experiments. In comparison, the concentrations used in ESI-MS titrations were much smaller (Table [1](#Tab1){ref-type="table"}). Furthermore, DMSO was used systematically in the ESI-MS experiments to prevent aggregation, whereas this was avoided in the ITC experiments because any discrepancy in the DMSO concentrations in the syringe and in the measurement cell is a common source of parasitic heat signal (heat of dilution). A possible explanation for the observed discrepancy between the two techniques is thus linked to this solubility problem and to segregation of the peptides in the ITC experiments into a solubilized fraction (probably *ca.* 80% according to the values of *f* ~1~ in Supplementary Figure [S10](#MOESM1){ref-type="media"}) and a more or less aggregated fraction (*ca.* 20%) that would be unable to interact with the protein. This is a conclusion of broad interest given the increasing importance of ITC for the characterization of molecular interactions. Clearly, additional investigations are needed for a better description of such situations. In particular, one might consider that the ITC model with two modes of binding could merely be an efficient numerical description of 'abnormal' ITC titration curves and that a more sensible model should take into account how each peptide is solubilized, which might require taking into account more or less slow kinetics.

One major lesson from this work is that a homodimer having two identical and independent binding sites is very favorable for deriving the *K* ~*d*~ and the probability *P* of GPD by ESI-MS experiments. We are confident that this should hold true for any situation neither involving too low affinity nor too important GPD; to which extent remains to be evaluated. In the general situation where the favorable feature of a homodimer does not exist, one may imagine to obtain dimers artificially, for example by tandem expression of two monomers separated by a short flexible linker. Obviously, one cannot expect this to be a common practical solution due to the additional necessary work and to possible folding problems. However, one may hope that the technical possibilities of linking protein monomers (for example by specific N- or C-term 'adhesive' tags) will expand sufficiently to transform ESI-MS into a competitive routine method for *K* ~*d*~ determination. Various lines of investigation currently pursued by several laboratories add weight to this suggestion \[[@CR24]--[@CR26]\]. Of course, only ITC allows measuring directly both the *K* ~*d*~ and the *ΔH*, and thus only ITC allows to obtain the complete thermodynamic signature of an interaction; however, in view of the problems described in this work, using both methods in parallel may well be the best way of avoiding wrong interpretations in difficult situations. In particular, only ESI-MS can tell unambiguously whether a non-simple binding mechanism requires considering either two binding modes competing for the same site, or the binding on different sites.
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